SAMS (Structure Aided Design and Multiplex Screening) is our high-throughput protein expression and purification screening system.

The structural hierarchy is the overarching list of variables that will affect protein structure and function.

Unmet needs for commercial proteins are identified via literature and database searches. We then use bioinformatics and structural analysis to design a variety of protein sequences/structures based on variables from the structural hierarchy.

Integrity, signal peptide, codons, etc. are analyzed using structural informatics and 3D modeling to determine how they will influence all four levels of protein structure.

The optimal protein configuration is identified from large search spaces of protein configurations and expression conditions. We prioritize natural protein configuration, yield, and bioactivity.

Protein designs are tested for bioactivity in multiple cell types/settings. Because we ensure protein function in multiple settings, you can be confident that the protein you purchase will work for your application.

Advantages of SAMS Platform

KACTUS recombinant proteins are designed and manufactured in-house, giving a high level of control over every step from protein engineering to product validation. We test each prodcut for bioactivity throughout the development process to ensure function in multiple in vitro settings. Each batch undergoes strict quality control testing including purity, activity, and endotoxin. Our high level of control results in superior batch to batch consistency. Moreover, the majority of our products are expressed using mammalian cell lines, allowing for post-translational modification, native protein conformation, and low endotoxin levels.

Vertical integration of protein engineering & manufacturing

Mammalian cell line expression systems

Comprehensive quality control testing

Batch to Batch Consistency

Fig 1. Imobilized Human DDL3, His Tag at 0.1µg/mL (100µl/well) on the plate. Dose response curve for Anti-DDL3 Antibody, hFc Tag with an EC50 of 5.0, 4.5 and 5.0 ng/mL respectively determined by ELISA

Fig 2. Immobilized Human Siglec-10, His Tag at 0.5µg/mL (100µl/well) Dose response curve for Anti-Siglec-10 Ab., hFc Tag with an EC50 OF 7.3, 7.7 and 7.4ng/mL, respectively asgetermined by ELISA

Fig 3. Immobilized Human CD4 at 0.5µg/mL (100µl/well) on the plate. Dose response curve for Anti-CD4 Antibody, hFc Tag with an EC50 OF 10.2, 10.6 and 10.6 ng/mL respectively as determined by ELISA